Exhibit 99
Wright Medical Group, Inc. Reports Results for First Quarter Ended March 31,
2005
ARLINGTON, Tenn.--(BUSINESS WIRE)--April 26, 2005--
Quarter's Net Sales are Highest in Company's History
Wright Medical Group, Inc. (NASDAQ:WMGI), a global orthopaedic
medical device company specializing in the design, manufacture and
marketing of reconstructive joint devices and biologics, today
reported financial results for its first quarter ended March 31, 2005.
Net sales totaled $82.6 million during the first quarter ended
March 31, 2005, representing a 10% increase over net sales of $74.9
million during the first quarter of 2004. First quarter net sales
achieved a record level for any quarter in the Company's history.
Excluding the impact of foreign currency, net sales increased 9%
during the first quarter. Net income for the first quarter of 2005
totaled $7.3 million or $.21 per diluted share, an increase of 11% per
share, compared to net income of $6.6 million or $.19 per diluted
share during the first quarter of 2004.
Laurence Y. Fairey, President and Chief Executive Officer
commented, "We are very pleased with our operating performance during
the first quarter, which achieved the upper end of our outlook ranges
for both net sales and earnings per share. Domestic first quarter net
sales results reflect continued growth in all of our product lines.
Our hip business, which grew by 17% globally and 28% domestically in
the first quarter, continues to benefit from one of the most
innovative product portfolios in the industry, including our advanced
hard bearing surface products and stem offerings that incorporate our
proprietary modular neck technologies. As previously discussed, we
continue to expect the sales growth of our biologics and extremities
businesses to accelerate as the year progresses, aided by sales and
marketing initiatives and new product launches."
Mr. Fairey continued, "Also consistent with previous guidance, we
continue to expect our earnings per share growth to accelerate in the
second half of '05 aided by both higher sales gains and by a reduced
impact of expenses related to new product launches and changes in our
European sales organization. Altogether, we are on track for another
solid year of both top- and bottom-line performance."
Sales Review
Globally, the Company experienced growth across all of its major
product lines during the first quarter of 2005, with the Company's hip
product line again posting an outstanding growth rate. Specifically,
global net sales of the Company's hip, knee, extremity and biologics
product lines increased by 17%, 9%, 6% and 5%, respectively, during
the first quarter of 2005 when compared to the first quarter of 2004.
Domestic sales totaled $49.8 million during the first quarter of
2005 representing an increase of 12% compared to 2004. First quarter
domestic sales of the Company's hip, knee, extremity and biologics
product lines reflected growth of 28%, 10%, 8% and 2%, respectively.
International sales totaled $32.8 million during the first
quarter, an increase of 8% compared to the first quarter of 2004. The
Company's international sales results included favorable foreign
currency impacts totaling approximately $1.2 million. A reconciliation
of GAAP to "as adjusted" results is included in the attached financial
tables.
Outlook
The Company has narrowed its previously-communicated sales target
for the full year 2005 to a range of $335 million to $344 million,
representing a sales growth objective of approximately 13% to 16%, and
has narrowed its previously-communicated full year earnings per share
outlook to a target range of $0.87 to $0.90 per diluted share,
representing annual growth of approximately 16% to 20% compared to
2004 net income, as adjusted, per diluted share. These
newly-established net sales and earnings targets reflect increases to
their respective lower ends when compared to the Company's
previously-communicated targets.
The Company's anticipated targets for the second quarter of 2005
for net sales are in the range of $84 million to $86 million,
representing sales growth objectives between approximately 11% and 14%
for the quarter, with earnings per share results ranging from $0.19 to
$0.21 per diluted share. These targets for the second quarter and full
year of 2005 exclude the effect of possible future acquisitions or
other material future business developments.
A reconciliation of 2004 net income, as adjusted, per diluted
share is available in the "Corporate - Investor Information -
Supplemental Financial Information" section of the Company's website
located at www.wmt.com.
The Company's anticipated targets for net sales and earnings per
share are forward-looking statements. They are subject to various
risks and uncertainties that could cause the Company's actual results
to differ materially from the anticipated targets. The anticipated
targets are not predictions of the Company's actual performance. See
the cautionary information about forward-looking statements in the
"Safe-Harbor Statement" section of this press release.
Conference Call
As previously announced, the Company will host a conference call
starting at 3:30 p.m. (Central Time) today. The live dial-in number
for the call is 800-289-0743 (domestic) or 913-981-5546
(international). To access a simultaneous webcast of the conference
call via the internet, go to the "Corporate - Investor Information"
section of the Company's website located at www.wmt.com. A replay of
the conference call by telephone will be available starting at 7:30
p.m. (Central Time) today and continuing until 12:00 a.m. (Central
Time) on May 3, 2005. To hear this replay, dial 888-203-1112
(domestic) or 719-457-0820 (international) and enter the registration
number 8714849. A replay of the conference call will also be available
via the internet starting today and continuing for at least 12 months.
To access a replay of the conference call via the internet, go to the
"Corporate - Investor Information - Audio Archives" section of the
Company's website located at www.wmt.com.
The conference call may include a discussion of non-GAAP financial
measures. Reference is made to the most directly comparable GAAP
financial measures, the reconciliation of the differences between the
two financial measures, and the other information included in this
press release or otherwise available in the "Corporate - Investor
Information - Supplemental Financial Information" section of the
Company's website located at www.wmt.com.
The conference call may include forward-looking statements. See
the cautionary information about forward-looking statements in the
"Safe-Harbor Statement" section of this press release.
Non-GAAP Financial Measures
The Company uses non-GAAP financial measures, such as net sales,
excluding the impact of foreign currency, gross profit, as adjusted,
operating income, as adjusted, net income, as adjusted and net income,
as adjusted, per diluted share. The Company's management believes that
the presentation of these measures provides useful information to
investors. These measures may assist investors in evaluating the
Company's operations, period over period. The measures exclude such
items as business development activities, including purchased
in-process research and development, and the financial impact of
significant litigation, which may be highly variable, difficult to
predict and of a size that could have substantial impact on the
Company's reported results of operations for a period. Management uses
these measures internally for evaluation of the performance of the
business, including the allocation of resources and the evaluation of
results relative to employee performance compensation targets.
Investors should consider these non-GAAP measures only as a supplement
to, not as a substitute for or as superior to, measures of financial
performance prepared in accordance with GAAP.
Safe-Harbor Statement
This press release contains "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All statements made in this press release, other than statements of
historical fact, are forward-looking statements. Forward-looking
statements reflect management's current knowledge, assumptions,
beliefs, estimates, and expectations and express management's current
views of future performance, results, and trends. The Company wishes
to caution readers that actual results might differ materially from
those described in the forward-looking statements. Forward-looking
statements are subject to a number of risks and uncertainties,
including the factors discussed in the Company's filings with the
Securities and Exchange Commission (including the Company's annual
report on Form 10-K for the year ended December 31, 2004 under the
heading, "Factors Affecting Future Operating Results"), which could
cause the Company's actual results to materially differ from those
described in the forward-looking statements. Although the Company
believes that the forward-looking statements are accurate, there can
be no assurance that any forward-looking statement will prove to be
accurate. A forward-looking statement should not be regarded as a
representation by the Company that the results described therein will
be achieved. The Company wishes to caution readers not to place undue
reliance on any forward-looking statement. The forward-looking
statements are made as of the date of this press release. The Company
assumes no obligation to update any forward-looking statement after
this date.
Wright Medical Group, Inc. is a global orthopaedic medical device
company specializing in the design, manufacture and marketing of
reconstructive joint devices and biologics. The Company has been in
business for more than 50 years and markets its products in over 60
countries worldwide. For more information about Wright Medical, visit
the Company's website at www.wmt.com.
Wright Medical Group, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except per share data--unaudited)
Three Months Ended
----------------------
March 31, March 31,
2005 2004
----------- ----------
Net sales $ 82,601 $ 74,917
Cost of sales 22,777 20,386
----------- ----------
Gross profit 59,824 54,531
Operating expenses:
Selling, general and administrative 41,668 37,134
Research and development 4,897 4,982
Amortization of intangible assets 1,059 942
Stock-based expense(1) 212 424
----------- ----------
Total operating expenses 47,836 43,482
----------- ----------
Operating income 11,988 11,049
Interest expense, net 90 284
Other expense, net 174 38
----------- ----------
Income before income taxes 11,724 10,727
Provision for income taxes 4,455 4,113
----------- ----------
Net income $ 7,269 $ 6,614
=========== ==========
Net income per share, basic $ 0.21 $ 0.20
=========== ==========
Net income per share, diluted $ 0.21 $ 0.19
=========== ==========
Weighted-average number of common shares
outstanding, basic 33,875 33,077
=========== ==========
Weighted-average number of common shares
outstanding, diluted 35,201 35,241
=========== ==========
(1) Amounts presented as stock-based expense consist of; cost of sales
totaling $11 and $27 for the three months ended March 31, 2005 and
2004, respectively; selling, general and administrative expenses
of $201 and $371 for the three months ended March 31, 2005 and
2004, respectively; and research and development expenses of $0
and $26 for the three months ended March 31, 2005 and 2004,
respectively.
Wright Medical Group, Inc.
Consolidated Sales Analysis
(dollars in thousands--unaudited)
Three Months Ended
-------------------------------
March 31, March 31, %
2005 2004 change
----------- --------- ---------
Geographic
- ----------
Domestic $ 49,762 $ 44,377 12.1%
International 32,839 30,540 7.5%
----------- --------- ---------
Total net sales $ 82,601 $ 74,917 10.3%
=========== ========= =========
Product Line
- ------------
Hip products $ 29,170 $ 24,861 17.3%
Knee products 24,806 22,739 9.1%
Biologics products 15,413 14,720 4.7%
Extremity products 9,847 9,254 6.4%
Other 3,365 3,343 0.7%
----------- --------- ---------
Total net sales $ 82,601 $ 74,917 10.3%
=========== ========= =========
Wright Medical Group, Inc.
Reconciliation of Net Sales to Net Sales
Excluding the Impact of Foreign Currency
(dollars in thousands--unaudited)
Three Months Ended
March 31, 2005
-------------------
Net sales, as reported $ 82,601
Less: Currency impact as compared to
respective prior period (1,221)
-------------------
Net sales, excluding the impact of foreign
currency $ 81,380
===================
Wright Medical Group, Inc.
Condensed Consolidated Balance Sheets
(dollars in thousands--unaudited)
March 31, December 31,
2005 2004
----------- -------------
Assets
Current assets:
Cash and cash equivalents $ 88,036 $ 83,470
Accounts receivable, net 63,386 61,662
Inventories 78,500 76,269
Prepaid expenses and other current assets 34,441 33,621
----------- -------------
Total current assets 264,363 255,022
----------- -------------
Property, plant and equipment, net 70,414 70,207
Intangible assets, net 24,362 25,985
Other assets 10,727 9,944
----------- -------------
Total assets $ 369,866 $ 361,158
=========== =============
Liabilities and stockholders' equity
Current liabilities:
Accounts payable $ 15,476 $ 13,969
Accrued expenses and other current
liabilities 48,465 45,256
Current portion of long-term obligations 6,230 6,331
----------- -------------
Total current liabilities 70,171 65,556
----------- -------------
Long-term obligations 5,639 5,952
Other liabilities 13,464 13,581
----------- -------------
Total liabilities 89,274 85,089
----------- -------------
Stockholders' equity 280,592 276,069
----------- -------------
Total liabilities and stockholders'
equity $ 369,866 $ 361,158
=========== =============
CONTACT: Wright Medical Group, Inc., Arlington
John K. Bakewell, 901-867-4527